Amedica and Celling Biosciences will co-develop biologically-enhanced spinal fusion devices based on silicon nitride technology plus stem cell-based therapies.
Thus far, Celling Biosciences’ in vivo research indicates that mesenchymal stem cells may be optimized and proliferate when using silicon nitride vs. PEEK and titanium biomaterial. Studies suggest that the silicon nitride micro-environment promotes better cell adhesion and compatibility, with 5x greater cell adhesion vs. PEEK.
Following completion of initial research, Celling will translate early findings to clinical trials in spinal and orthopaedic applications.
Source: Amedica Corporation
Amedica and Celling Biosciences will co-develop biologically-enhanced spinal fusion devices based on silicon nitride technology plus stem cell-based therapies.
Thus far, Celling Biosciences' in vivo research indicates that mesenchymal stem cells may be optimized and proliferate when using silicon nitride vs. PEEK and titanium...
Amedica and Celling Biosciences will co-develop biologically-enhanced spinal fusion devices based on silicon nitride technology plus stem cell-based therapies.
Thus far, Celling Biosciences’ in vivo research indicates that mesenchymal stem cells may be optimized and proliferate when using silicon nitride vs. PEEK and titanium biomaterial. Studies suggest that the silicon nitride micro-environment promotes better cell adhesion and compatibility, with 5x greater cell adhesion vs. PEEK.
Following completion of initial research, Celling will translate early findings to clinical trials in spinal and orthopaedic applications.
Source: Amedica Corporation
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
